Lilly not slashing force like its rivals

Share this article:
Eli Lilly CEO Sidney Taurel said the company does not plan any major changes to its sales force, even as rivals cut jobs.

“We won’t grow our sales force,” Taurel said in an interview with the cable network CNBC. “There has been some reduction…of our sales force. But we don’t see major decreases.”

Taurel said Lilly has already decreased its total work force by 4,500, or 10%, since 2004.

Late 2006, Pfizer announced cuts to its US and European sales forces by at least 20%. AstraZeneca said it plans to cut 3,000 jobs, or 4.6% of its workforce. Abbott also announced the phasing out of “several hundred” primary care rep positions.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.